The initial treatment of Parkinson's disease should begin with levodopa
Identifieur interne :
002D67 ( PascalFrancis/Corpus );
précédent :
002D66;
suivant :
002D68
The initial treatment of Parkinson's disease should begin with levodopa
Auteurs : W. J. WeinerSource :
-
Movement disorders [ 0885-3185 ] ; 1999.
RBID : Pascal:99-0475653
Descripteurs français
English descriptors
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
| A01 | 01 | 1 | | @0 0885-3185 |
|---|
| A03 | | 1 | | @0 Mov. disord. |
|---|
| A05 | | | | @2 14 |
|---|
| A06 | | | | @2 5 |
|---|
| A08 | 01 | 1 | ENG | @1 The initial treatment of Parkinson's disease should begin with levodopa |
|---|
| A11 | 01 | 1 | | @1 WEINER (W. J.) |
|---|
| A14 | 01 | | | @1 Department of Neurology, University of Miami School of Medicine @2 Miami, Florida @3 USA @Z 1 aut. |
|---|
| A20 | | | | @1 716-724 |
|---|
| A21 | | | | @1 1999 |
|---|
| A23 | 01 | | | @0 ENG |
|---|
| A43 | 01 | | | @1 INIST @2 20953 @5 354000089971250020 |
|---|
| A44 | | | | @0 0000 @1 © 1999 INIST-CNRS. All rights reserved. |
|---|
| A45 | | | | @0 60 ref. |
|---|
| A47 | 01 | 1 | | @0 99-0475653 |
|---|
| A60 | | | | @1 P |
|---|
| A61 | | | | @0 A |
|---|
| A64 | 01 | 1 | | @0 Movement disorders |
|---|
| A66 | 01 | | | @0 USA |
|---|
| C02 | 01 | X | | @0 002B02B06 |
|---|
| C03 | 01 | X | FRE | @0 Parkinson maladie @5 01 |
|---|
| C03 | 01 | X | ENG | @0 Parkinson disease @5 01 |
|---|
| C03 | 01 | X | SPA | @0 Parkinson enfermedad @5 01 |
|---|
| C03 | 02 | X | FRE | @0 Lévodopa @5 04 |
|---|
| C03 | 02 | X | ENG | @0 Levodopa @5 04 |
|---|
| C03 | 02 | X | SPA | @0 Levodopa @5 04 |
|---|
| C03 | 03 | X | FRE | @0 Antiparkinsonien @5 05 |
|---|
| C03 | 03 | X | ENG | @0 Antiparkinson agent @5 05 |
|---|
| C03 | 03 | X | SPA | @0 Antiparkinsoniano @5 05 |
|---|
| C03 | 04 | X | FRE | @0 Chimiothérapie @5 16 |
|---|
| C03 | 04 | X | ENG | @0 Chemotherapy @5 16 |
|---|
| C03 | 04 | X | SPA | @0 Quimioterapia @5 16 |
|---|
| C03 | 05 | X | FRE | @0 Traitement @5 17 |
|---|
| C03 | 05 | X | ENG | @0 Treatment @5 17 |
|---|
| C03 | 05 | X | SPA | @0 Tratamiento @5 17 |
|---|
| C03 | 06 | X | FRE | @0 Homme @5 20 |
|---|
| C03 | 06 | X | ENG | @0 Human @5 20 |
|---|
| C03 | 06 | X | SPA | @0 Hombre @5 20 |
|---|
| C03 | 07 | X | FRE | @0 Précoce @5 23 |
|---|
| C03 | 07 | X | ENG | @0 Early @5 23 |
|---|
| C03 | 07 | X | SPA | @0 Precoz @5 23 |
|---|
| C07 | 01 | X | FRE | @0 Système nerveux pathologie @5 37 |
|---|
| C07 | 01 | X | ENG | @0 Nervous system diseases @5 37 |
|---|
| C07 | 01 | X | SPA | @0 Sistema nervioso patología @5 37 |
|---|
| C07 | 02 | X | FRE | @0 Système nerveux central pathologie @5 38 |
|---|
| C07 | 02 | X | ENG | @0 Central nervous system disease @5 38 |
|---|
| C07 | 02 | X | SPA | @0 Sistema nervosio central patología @5 38 |
|---|
| C07 | 03 | X | FRE | @0 Encéphale pathologie @5 39 |
|---|
| C07 | 03 | X | ENG | @0 Cerebral disorder @5 39 |
|---|
| C07 | 03 | X | SPA | @0 Encéfalo patología @5 39 |
|---|
| C07 | 04 | X | FRE | @0 Extrapyramidal syndrome @5 40 |
|---|
| C07 | 04 | X | ENG | @0 Extrapyramidal syndrome @5 40 |
|---|
| C07 | 04 | X | SPA | @0 Extrapiramidal síndrome @5 40 |
|---|
| C07 | 05 | X | FRE | @0 Maladie dégénérative @5 41 |
|---|
| C07 | 05 | X | ENG | @0 Degenerative disease @5 41 |
|---|
| C07 | 05 | X | SPA | @0 Enfermedad degenerativa @5 41 |
|---|
| N21 | | | | @1 305 |
|---|
|
|---|
Format Inist (serveur)
| NO : | PASCAL 99-0475653 INIST |
|---|
| ET : | The initial treatment of Parkinson's disease should begin with levodopa |
|---|
| AU : | WEINER (W. J.) |
|---|
| AF : | Department of Neurology, University of Miami School of Medicine/Miami, Florida/Etats-Unis (1 aut.) |
|---|
| DT : | Publication en série; Niveau analytique |
|---|
| SO : | Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1999; Vol. 14; No. 5; Pp. 716-724; Bibl. 60 ref. |
|---|
| LA : | Anglais |
|---|
| CC : | 002B02B06 |
|---|
| FD : | Parkinson maladie; Lévodopa; Antiparkinsonien; Chimiothérapie; Traitement; Homme; Précoce |
|---|
| FG : | Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative |
|---|
| ED : | Parkinson disease; Levodopa; Antiparkinson agent; Chemotherapy; Treatment; Human; Early |
|---|
| EG : | Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease |
|---|
| SD : | Parkinson enfermedad; Levodopa; Antiparkinsoniano; Quimioterapia; Tratamiento; Hombre; Precoz |
|---|
| LO : | INIST-20953.354000089971250020 |
|---|
| ID : | 99-0475653 |
|---|
Links to Exploration step
Pascal:99-0475653
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The initial treatment of Parkinson's disease should begin with levodopa</title>
<author><name sortKey="Weiner, W J" sort="Weiner, W J" uniqKey="Weiner W" first="W. J." last="Weiner">W. J. Weiner</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Miami School of Medicine</s1>
<s2>Miami, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14><publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">99-0475653</idno>
<date when="1999">1999</date>
<idno type="stanalyst">PASCAL 99-0475653 INIST</idno>
<idno type="RBID">Pascal:99-0475653</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002D67</idno>
</publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The initial treatment of Parkinson's disease should begin with levodopa</title>
<author><name sortKey="Weiner, W J" sort="Weiner, W J" uniqKey="Weiner W" first="W. J." last="Weiner">W. J. Weiner</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Miami School of Medicine</s1>
<s2>Miami, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14><series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1999">1999</date>
</imprint><seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Early</term>
<term>Human</term>
<term>Levodopa</term>
<term>Parkinson disease</term>
<term>Treatment</term>
</keywords><keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Homme</term>
<term>Précoce</term>
</keywords><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01><fA03 i2="1"><s0>Mov. disord.</s0>
</fA03><fA08 i1="01" i2="1" l="ENG"><s1>The initial treatment of Parkinson's disease should begin with levodopa</s1>
</fA08><fA11 i1="01" i2="1"><s1>WEINER (W. J.)</s1>
</fA11><fA14 i1="01"><s1>Department of Neurology, University of Miami School of Medicine</s1>
<s2>Miami, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14><fA20><s1>716-724</s1>
</fA20><fA21><s1>1999</s1>
</fA21><fA23 i1="01"><s0>ENG</s0>
</fA23><fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000089971250020</s5>
</fA43><fA44><s0>0000</s0>
<s1>© 1999 INIST-CNRS. All rights reserved.</s1>
</fA44><fA45><s0>60 ref.</s0>
</fA45><fA47 i1="01" i2="1"><s0>99-0475653</s0>
</fA47><fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64><fA66 i1="01"><s0>USA</s0>
</fA66><fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02><fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03><fC03 i1="02" i2="X" l="FRE"><s0>Lévodopa</s0>
<s5>04</s5>
</fC03><fC03 i1="02" i2="X" l="ENG"><s0>Levodopa</s0>
<s5>04</s5>
</fC03><fC03 i1="02" i2="X" l="SPA"><s0>Levodopa</s0>
<s5>04</s5>
</fC03><fC03 i1="03" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>05</s5>
</fC03><fC03 i1="03" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>05</s5>
</fC03><fC03 i1="03" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>05</s5>
</fC03><fC03 i1="04" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>16</s5>
</fC03><fC03 i1="04" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>16</s5>
</fC03><fC03 i1="04" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>16</s5>
</fC03><fC03 i1="05" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03><fC03 i1="05" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03><fC03 i1="05" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03><fC03 i1="06" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03><fC03 i1="06" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03><fC03 i1="06" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03><fC03 i1="07" i2="X" l="FRE"><s0>Précoce</s0>
<s5>23</s5>
</fC03><fC03 i1="07" i2="X" l="ENG"><s0>Early</s0>
<s5>23</s5>
</fC03><fC03 i1="07" i2="X" l="SPA"><s0>Precoz</s0>
<s5>23</s5>
</fC03><fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07><fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07><fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07><fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07><fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07><fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07><fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07><fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07><fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07><fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07><fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07><fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07><fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07><fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07><fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07><fN21><s1>305</s1>
</fN21><server><NO>PASCAL 99-0475653 INIST</NO>
<ET>The initial treatment of Parkinson's disease should begin with levodopa</ET>
<AU>WEINER (W. J.)</AU>
<AF>Department of Neurology, University of Miami School of Medicine/Miami, Florida/Etats-Unis (1 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1999; Vol. 14; No. 5; Pp. 716-724; Bibl. 60 ref.</SO>
<LA>Anglais</LA>
<CC>002B02B06</CC>
<FD>Parkinson maladie; Lévodopa; Antiparkinsonien; Chimiothérapie; Traitement; Homme; Précoce</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative</FG>
<ED>Parkinson disease; Levodopa; Antiparkinson agent; Chemotherapy; Treatment; Human; Early</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease</EG>
<SD>Parkinson enfermedad; Levodopa; Antiparkinsoniano; Quimioterapia; Tratamiento; Hombre; Precoz</SD>
<LO>INIST-20953.354000089971250020</LO>
<ID>99-0475653</ID>
</server>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D67 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002D67 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:99-0475653
|texte= The initial treatment of Parkinson's disease should begin with levodopa
}}
| This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024 |  |
